



ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH



—CME ACCREDITED—

MICHIGAN MEDICINE

UPDATES IN BREAST CANCER MANAGEMENT SYMPOSIUM

Saturday, September 19, 2026

8:00 AM – 4:00 PM

Vanguard Hotel
201 Glen Avenue
Ann Arbor, MI 48104



Scan to register

Click here to register (<https://rsvp.umich.edu/ZgKvgn>)



Keynote speaker:
Kari Wisinski, MD
UW Carbone Cancer Center

In partnership with:



MORNING SESSION

8:00 am: **Breakfast, Check-In and Networking**

WELCOME AND INTRODUCTIONS

8:40 am: **Erin Cobain, MD; Monika Burness, MD;**
Melissa Pilewskie, MD
University of Michigan Health Rogel Cancer Center

METABOLIC MODULATION IN BREAST CANCER SURVIVORS

9:00 am: **GLP-1 Agonists: An Emerging Partner in Breast Cancer
Therapy and Prevention?**
Sherry Shen, MD, Memorial Sloan Kettering Cancer Center

9:30 am: **Motion Matters: The Role of Exercise in Breast Cancer
Survivorship**
Lee Jones, PhD, City of Hope Cancer Center

10:00 am: **Coffee and Networking Break**

LESS IS MORE? REDUCING TREATMENT RELATED TOXICITIES FOR LOW-RISK PATIENTS

10:10 am: **Right-Sizing Surgery: Considerations for De-escalated
Axillary Surgery in Low-Risk Breast Cancer**
Melissa Pilewskie, MD, Rogel Cancer Center

10:40 am: **Scaling Back: Key Radiation Oncology Considerations in
Low-Risk Breast Cancer**
Michelle Tibbs, MD, Rogel Cancer Center

11:10 am: **The Ripple Effect: How De-escalation of Surgery and
Radiation Approaches Shape Systemic Therapy Decisions**
Lynn Henry, MD, Rogel Cancer Center



MICHIGAN MEDICINE UPDATES IN BREAST CANCER MANAGEMENT SYMPOSIUM

Saturday, September 19, 2026



ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH

Target Audience

This symposium is intended for nurses, physicians, physicians in training, (residents/fellows), medical students, nurse practitioners, other Healthcare professional, physician assistant, physician Resident, scientists and advanced practice providers in managing breast cancer patients.

Activity Description

The Michigan Medicine Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The Rogel catchment area includes the entire State of Michigan, its ~10M residents, and ~750 community medical oncologists. The Mission of the Rogel is to reduce the burden of cancer and advance health equity through transdisciplinary collaboration in research, education, patient care and community outreach.

Objectives

Upon completion of this program, the participant will:

1) Apply evolving clinical trial data to breast cancer treatment decisions. 2) Evaluate treatment options based on efficacy, toxicity, and patient-centered considerations. 3) Integrate emerging therapies into clinical management of high-risk and complex cases. 4) Implement evidence-based strategies to improve survivorship and manage treatment-related toxicities.

Faculty Planners

Erin Cobain, MD; Monika Burness, MD; Melissa Pilewskie, MD

Financial Disclosure Information

Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

No cost to attend.

11:40 am: **Case-Based Panel Discussion**

AFTERNOON SESSION

12:00 pm: **Lunch, Networking, Visit Exhibitors**

12:45 pm: **Timing is Everything: Harnessing Antibody Drug Conjugates Early Stage and Metastatic Breast Cancer Care**

Kari Wisinski, MD, UW Carbone Cancer Center

1:15 pm: **Crossing the Divide: Systemic Therapy Decisions in Breast Cancer with Brain Metastases**

Haythem Ali, MD, Henry Ford Health Cancer Institute

1:45 pm: **Coffee Break, Networking, Visit Exhibitors**

RAISING THE BAR: BETTER OUTCOMES FOR HIGH-RISK EARLY-STAGE BREAST CANCER

2:00 pm: **Advancing Adjuvant Endocrine Strategies: Integrating CDK4/6 Inhibitors, Oral SERDs, and Emerging Therapies**
Megan Kruse, MD, Cleveland Clinic Tussing Cancer Center

2:30 pm: **Gene Expression Profiling 2.0: Advancing Personalized Systemic Therapy Decisions in High-Risk Hormone Receptor Positive Breast Cancer Beyond Chemotherapy**
Erin Cobain, MD, Rogel Cancer Center

3:00 pm: **From Detection to Direction: The Promise of ctDNA in Management of Early Breast Cancer**
Monika Burness, MD, Rogel Cancer Center

3:30 pm: **Case-Based Panel Discussion**

3:45 pm: **Closing Remarks**

Accreditation and Credit Designation The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.